Search research articles
Contact Us
Filters
Showing results (151-160 of 183) with videos related to
Page
of 19
Sort By:
Clinical Nuclear Medicine
|
June 4, 2025
Prognostic Value of 18F-FDG PET/CT in Neoadjuvant PD-1 Inhibitor-treated NSCLC: A Five-year Follow-up Study
Xiuli Tao, Qian Zhang, Ning Li, et al.
Peptides
|
December 18, 2017
Vasodilator and hypotensive effects of the spider peptide Lycosin-I in vitro and in vivo
Binbin Ma, Zhouhuan Xi, Jiahui Li, et al.
NPJ Precision Oncology
|
December 10, 2020
Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes
Yun Ling, Ning Li, Lin Li, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|
January 18, 2020
[Acceptance and Related Causes of Clinical Trials among Cancer Patients in China]
Huiyao Huang, Qi Fan, Hong Fang, et al.
Thoracic Cancer
|
January 11, 2018
Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma
Jia Zhong, Qiwen Zheng, Emei Gao, et al.
Scientific Reports
|
June 23, 2015
ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
Zhijie Wang, Zhenxiang Li, Xiaosheng Ding, et al.
Journal for Immunotherapy of Cancer
|
July 28, 2019
Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer
Liangliang Cai, Hua Bai, Jianchun Duan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 19, 2017
Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs)
Jia Zhong, Lei Li, Zhijie Wang, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu
|
January 23, 2018
Survival difference between <i>EGFR</i> Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis
Minglei Zhuo, Qiwen Zheng, Jun Zhao, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 30, 2009
EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer
Meina Wu, Jun Zhao, Sonya Wei Song, et al.
Page
of 19
Search research articles
Search
Showing results (151-160 of 183) with videos related to
Sort By:
Page
of 19
Clinical Nuclear Medicine
|
June 4, 2025
Prognostic Value of 18F-FDG PET/CT in Neoadjuvant PD-1 Inhibitor-treated NSCLC: A Five-year Follow-up Study
Xiuli Tao, Qian Zhang, Ning Li, et al.
Peptides
|
December 18, 2017
Vasodilator and hypotensive effects of the spider peptide Lycosin-I in vitro and in vivo
Binbin Ma, Zhouhuan Xi, Jiahui Li, et al.
NPJ Precision Oncology
|
December 10, 2020
Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes
Yun Ling, Ning Li, Lin Li, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|
January 18, 2020
[Acceptance and Related Causes of Clinical Trials among Cancer Patients in China]
Huiyao Huang, Qi Fan, Hong Fang, et al.
Thoracic Cancer
|
January 11, 2018
Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma
Jia Zhong, Qiwen Zheng, Emei Gao, et al.
Scientific Reports
|
June 23, 2015
ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
Zhijie Wang, Zhenxiang Li, Xiaosheng Ding, et al.
Journal for Immunotherapy of Cancer
|
July 28, 2019
Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer
Liangliang Cai, Hua Bai, Jianchun Duan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 19, 2017
Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs)
Jia Zhong, Lei Li, Zhijie Wang, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu
|
January 23, 2018
Survival difference between <i>EGFR</i> Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis
Minglei Zhuo, Qiwen Zheng, Jun Zhao, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 30, 2009
EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer
Meina Wu, Jun Zhao, Sonya Wei Song, et al.
Page
of 19